The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Halofuginone (HF) effectively inhibits anaplastic thyroid carcinoma (ATC) growth by targeting the EPRS-ATF4-COLI pathway. This study reveals HF as a potential therapeutic agent for aggressive thyroid cancer.
Area Of Science
- Oncology
- Molecular Biology
- Pharmacology
Background
- Anaplastic thyroid carcinoma (ATC) is a highly aggressive cancer requiring novel treatments.
- Halofuginone (HF) shows promise as an anticancer agent, but its efficacy in ATC is unexplored.
Purpose Of The Study
- Investigate the antitumor effects and mechanisms of HF in ATC.
- Identify potential therapeutic targets for ATC treatment.
Main Methods
- In vitro and in vivo assays (CCK8, colony formation, xenografts, organoids) assessed HF's efficacy.
- Drug affinity responsive target stability (DARTS), western blot, and IHC identified HF targets.
- Bioinformatics (GEPIA, GEO) and molecular analyses (RNA-seq, flow cytometry) elucidated mechanisms.
Main Results
- HF suppressed ATC cell proliferation and tumor growth in vivo.
- HF targets glutamyl-prolyl-tRNA-synthetase (EPRS), inducing amino acid starvation and reducing type I collagen (COLI) expression.
- HF inhibited metastasis by suppressing EMT and angiogenesis, and promoted apoptosis.
Conclusions
- HF demonstrates significant therapeutic potential for ATC.
- The EPRS-ATF4-COLI pathway is a promising biomarker and therapeutic target for ATC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...